The Relationship Between Sarcopenia and Cancer Chemotherapys
International Journal of Clinical Oncology and Cancer Research
Volume 5, Issue 1, March 2020, Pages: 10-15
Received: Jan. 19, 2020; Accepted: Mar. 30, 2020; Published: Apr. 14, 2020
Views 237      Downloads 72
Authors
Fufeng Zhang, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Department of General Medicine, Xiangya Hospital, Central South University, Changsha, China
Shasha Yang, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Qiong Chen, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Xiaoqin Lu, Department of Emergency, Xiangya Hospital, Central South University, Changsha, China
Article Tools
Follow on us
Abstract
As an independent disease, characterized by progressive and generalized loss of skeletal muscle mass, quality and strength, Sarcopenia has become a research hotspot in recent years, and its position in cancer patients has been increasingly valued by clinicians. Clarifying the relationship between Sarcopenia and chemotherapeutics in the treatment of cancer patients will help to formulate interventions for Sarcopenia to improve the quality of life and prolong survival period of cancer patients. In order to understand the relationship between Sarcopenia and cancer chemotherapy, we review from the following aspects. How is Sarcopenia diagnosed in cancer patients? How to evaluate Sarcopenia in cancer patients? What is the incidence of Sarcopenia in cancer patients? What is the relationship between the changes in body composition and the dose of chemotherapy in cancer patients? Whether there is a relationship between Sarcopenia and chemotherapy-related toxicity in cancer patients? Its role in leading to chemotherapy toxicity and its effect on the prognosis and survival in cancer patients. Whether chemotherapeutic drugs have an effect on the development of Sarcopenia in cancer patients, or whether certain types of chemotherapy drugs will affect Sarcopenia? Finally, the review also aims to describe interventions for Sarcopenia and their impact on the outcome of treatment for cancer patients.
Keywords
Sarcopenia, Cancer Chemotherapy, Toxicity, Prognosis
To cite this article
Fufeng Zhang, Shasha Yang, Qiong Chen, Xiaoqin Lu, The Relationship Between Sarcopenia and Cancer Chemotherapys, International Journal of Clinical Oncology and Cancer Research. Vol. 5, No. 1, 2020, pp. 10-15. doi: 10.11648/j.ijcocr.20200501.13
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Zhou CJ, Zhang FM, Zhang FY, et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy. J Surg Res. 2017; 211: 137-146.
[2]
Park YS, Kim JW, Kim BG, et al. Sarcopenia is associated with an increased risk of advanced colorectal neoplasia. Int J Colorectal Dis. 2017; 32 (4): 557-565.
[3]
Gioulbasanis I, Baracos VE, Giannousi Z, et al. Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol. 2011; 22 (4): 835-841.
[4]
Shoji F, Matsubara T, Kozuma Y, et al. Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. Anticancer Res. 2017; 37 (12): 6997-7003.
[5]
Shachar SS, Deal AM, Weinberg M, et al. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy. Clin Cancer Res. 2017; 23 (3): 658-665.
[6]
Mardas M, Stelmach-Mardas M, Madry R. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival. Support Care Cancer. 2017; 25 (3): 795-800.
[7]
Xiao DY, Luo S, O'Brian K, et al. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-celllymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016; 91 (10): 1002-1007.
[8]
Martucci RB, Barbosa MV, D'Almeida CA, et al. Undernutrition as independent predictor of early mortality in elderly cancer patients. Nutrition. 2017; 34: 65-70.
[9]
Varban OA. Concise Commentary: Visceral Obesity, Sarcopenia, and Cancer Surgery-Increasing Fitness Decreases Risk. Dig Dis Sci. 2018; 63 (6): 1631-1632.
[10]
Bozzetti F, Mariani L, Lo Vullo S; SCRINIO Working Group. The nutritional risk in oncology: a study of 1,453 cancer outpatients. Support Care Cancer. 2012; 20 (8): 1919–1928.
[11]
He´buterne X, Lemarie´ E, Michallet M et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014; 38 (2): 196–204.
[12]
Pressoir M, Desne´ S, Berchery D et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010; 102 (6): 966–971.
[13]
Mariani L, Lo Vullo S, Bozzetti F; SCRINIO Working Group. Weight loss in cancer patients: a plea for a better awareness of the issue. Support Care Cancer. 2012; 20 (2): 301–309.
[14]
Wie GA, Cho YA, Kim SY et al. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition. 2010; 26 (3): 263-268.
[15]
Roeland EJ, Ma JD, Nelson SH et al. Weight loss versus muscle loss: reevaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017; 25 (2): 365-369.
[16]
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12 (5): 489-95.
[17]
Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 47 (8): 755-763.
[18]
Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016; 54: 2-10.
[19]
Martin L, Birdsell L, Macdonald N et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31 (12): 1539-1547.
[20]
Rier HN, Jager A, Sleijfer S, et al. The prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist. 2016; pii: 2016-0066.
[21]
Taguchi S, Akamatsu N, Nakagawa T, et al. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2016; 14 (3): 237-243.
[22]
Sjøblom B, Grønberg BH, Wentzel-Larsen T et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016; 35 (6): 1386–1393.
[23]
Sabel MS, Lee J, Cai S et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011; 18 (13): 3579-3585.
[24]
Auclin E, Bourillon C, De Maio E, et al. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2017; 15 (3): 350-355.
[25]
Rollins KE, Tewari N, Ackner A et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016; 35 (5): 1103-1115.
[26]
Chu MP, Lieffers J, Ghosh S et al. Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy. J Cachexia Sarcopenia Muscle. 2017; 8 (2): 298-304.
[27]
Kitamura I, Koda M, Otsuka R et al. Six-year longitudinal changes in body composition of middle-aged and elderly Japanese: age and sex differences in appendicular skeletal muscle mass. Geriatr Gerontol Int. 2014; 14 (2): 354-361.
[28]
Hughes VA, Frontera WR, Wood M et al. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci. 2001; 56 (5): B209-B217.
[29]
Goodpaster BH, Park SW, Harris TB et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61 (10): 1059-1064.
[30]
Nattenmüller J, Wochner R, Muley T, et al. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients. PLoS One. 2017; 12 (1): e0169136.
[31]
Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications ofcancer therapy. Ann Oncol. 2018; 29 (suppl_2): ii1-ii9.
[32]
Du Bois D, Du Bois EF. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med (Chic). 1916; 17: 863-871.
[33]
Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9 (7): 629-635.
[34]
Prado CM, Lima IS, Baracos VE et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011; 67 (1): 93-101.
[35]
Shachar SS, Deal AM, Weinberg M et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane based chemotherapy for early stage breast cancer. Clin Cancer Res. 2017; 23 (14): 3537-3543.
[36]
Itoh S, Shirabe K, Matsumoto Y et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol. 2014; 21 (9): 3063-3068.
[37]
Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15 (8): 2920-2926.
[38]
Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015; 54 (3): 340-348.
[39]
Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014; 66 (4): 583-589.
[40]
Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity inpatients with locally advanced head and neck cancer. Oral Oncol. 2017; 71: 26-33.
[41]
Vega MC, Laviano A, Pimentel GD. Sarcopenia and chemotherapy-mediated toxicity. Einstein (Sao Paulo). 2016; 14 (4): 580-584.
[42]
Miyata H, Sugimura K, Motoori M, et al. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. Anticancer Res. 2017; 37 (6): 3053-3059.
[43]
Rier HN, Jager A, Meinardi MC, et al. Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment. Support Care Cancer. 2018; 26 (6): 1781-1789.
[44]
Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016; 57: 58-67.
[45]
Kitagawa M, Haji S, Amagai T. Elevated Serum AA/EPA Ratio as a Predictor of Skeletal Muscle Depletion in Cachexic Patients with Advanced Gastro-intestinal Cancers. In Vivo. 2017; 31 (5): 1003-1009.
[46]
Rutten IJ, Van Dijk DP, Kruitwagen RF, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival inovarian cancer patients. J Cachexia Sarcopenia Musle. 2016; 7 (4): 458-466.
[47]
Daly LE, Ní Bhuachalla ÉB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018; 9 (2): 315-325.
[48]
Cooper AB, Slack R, Fogelman D, et al. Characterization of Anthropometric changes that occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2015; 22 (7): 2416-2423.
[49]
Adams SC, Segal RJ, McKenzie DC, et al. Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2016; 158 (3): 497-507.
[50]
Krzymińska-Siemaszko R, Czepulis N, Lewandowicz M, et al. The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass. Int J Environ Res Public Health. 2015; 12 (9): 10558-10574.
[51]
Chen JA, Splenser A, Guillory B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015; 6 (2): 132-143.
[52]
De Spiegeleer A, Petrovic M, Boeckxstaens P, et al. Treating sarcopenia in clinical practice: where are we now? Acta Clin Belg. 2016; 71 (4): 197-205.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186